Anti-RIP antibody,Abcam,AB234845

Host

Rabbit

Reactivity

Human

Application

IP

Platform ID

BAB770030881

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-RIP antibody
Cat. No.AB234845
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIP
ClonalityPolyclonal
Concentration1 mg/mL Batch dependent concentration
ImmunogenRecombinant Full Length Protein corresponding to Mouse Ripk1.
PurityAffinity purification Protein G
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways (PubMed : 24557836, PubMed : 24813849, PubMed : 24813850, PubMed : 27819681, PubMed : 28842570, PubMed : 31511692, PubMed : 31827280, PubMed : 31827281, PubMed : 33397971). Exhibits kinase activity-dependent functions that regulate cell death and kinase-independent scaffold functions regulating inflammatory signaling and cell survival (PubMed : 24557836, PubMed : 24813849, PubMed : 24813850, PubMed : 28842570, PubMed : 31519886, PubMed : 31519887). Has kinase-independent scaffold functions : upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kappa-B pathway (PubMed : 31519886, PubMed : 31519887). Kinase activity is essential to regulate necroptosis and apoptosis, two parallel forms of cell death : upon activation of its protein kinase activity, regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which drives necroptosis (PubMed : 27819681, PubMed : 27819682, PubMed : 28842570, PubMed : 29440439, PubMed : 30988283, PubMed : 31519886, PubMed : 31519887). RIPK1 is required to limit CASP8-dependent TNFR1-induced apoptosis (PubMed : 24557836, PubMed : 24813849, PubMed : 24813850). In normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, a process mediated by RIPK3 component of complex IIb, which catalyzes phosphorylation of MLKL upon induction by ZBP1 (PubMed : 24557836, PubMed : 27819681, PubMed : 27819682, PubMed : 31358656). Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis (PubMed : 31358656). Required to inhibit apoptosis and necroptosis during embryonic development : acts by preventing the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8 (PubMed : 30185824, PubMed : 30867408). In addition to apoptosis and necroptosis, also involved in inflammatory response by promoting transcriptional production of pro-inflammatory cytokines, such as interleukin-6 (IL6) (PubMed : 31827280, PubMed : 31827281). Phosphorylates RIPK3 : RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (By similarity). Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (By similarity). Required for ZBP1-induced NF-kappa-B activation in response to DNA damage (PubMed : 12654725, PubMed : 19590578). See full target information Ripk1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.